International Scholarly Research Notices

Clinical Study

Sentinel Lymph Node Biopsy in Pure DCIS: Is It Necessary?

Table 1

Univariate analyses for predicting factors associated with the presence of sentinel lymph node biopsy (SLNB) in patients with pure ductal carcinoma in situ (DCIS).
FactorsUse of SLNB (+) (%) ( 𝑛 = 4 0 ) 𝑃 value
Age:0.611
 <50 ( 𝑛 = 3 0 ) versus β‰₯50 ( 𝑛 = 3 3 )18 (60%) versus 22 (66.7%)
Palpable mass*:0.017
  (βˆ’) versus (+)23 (44.2%) versus 16 (88.9%)
Tumor size:0.006
 ≀30 mm ( 𝑛 = 4 0 ) versus >30 mm
 ( 𝑛 = 2 3 )		20 (50%) versus 20 (87%)
Comedo necrosis*:0.026
 present ( 𝑛 = 3 1 ) versus absent
  ( 𝑛 = 2 6 )		24 (77.4%) versus 12 (46%)
Nuclear grade*:0.012
 low ( 𝑛 = 1 5 ) versus intermediate and
 high ( 𝑛 = 3 4 )		5 (33.3%) versus 25 (73.5%)
Type of surgery:0.001
 breast conservation ( 𝑛 = 3 1 ) versus
 mastectomy ( 𝑛 = 3 2 )		13 (41.9%) versus 27 (84.4%)
Multifocality/multicentricity:0.182
  (βˆ’) ( 𝑛 = 2 8 ) versus (+) ( 𝑛 = 3 4 )21 (75%) versus 19 (55.9%)
Estrogen receptor status*:0.622
  (+) ( 𝑛 = 2 1 ) versus (βˆ’) ( 𝑛 = 7 )17 (81%) versus 5 (71.4%)
Progesteron receptor status*:0.634
  (+) ( 𝑛 = 1 8 ) versus (βˆ’) ( 𝑛 = 1 0 )15 (83.3%) versus 7 (70%)
HER2/neu*:0.364
  (IHC 3+) or FISH (+) ( 𝑛 = 1 6 ) versus
   other ( 𝑛 = 9 )		11 (68.8%) versus 8 (88.9%)
*Unknown data were excluded from the analysis.